![]() |
市場調查報告書
商品編碼
1627660
筆針市場:預測(2025-2030)Pen Needle Market - Forecasts from 2025 to 2030 |
預計在預測期內,筆用針頭市場將以 9.27% 的複合年成長率成長,市場規模從 2025 年的 2,046,792,000 美元增至 2030 年的 3,189,012,000 美元。
筆式針頭廣泛用於將注射藥物注射到體內。慢性病盛行率上升預計將成為預測期內市場成長的主要驅動力之一。然而,替代品的供應預計將限制未來幾年的市場成長。
筆針市場促進因素
癌症和糖尿病等慢性病盛行率的增加是預測期內市場成長的主要驅動力之一。根據國際糖尿病聯盟的報告,20歲至79歲的糖尿病患者人數將從2017年的4.25億增加到2022年的5.37億,到2045年將增加到7.83億。
此外,糖尿病日益增加的經濟負擔和全球醫療保健支出的增加預計也將增加未來幾年對血糖監測快速診斷試劑套件的需求。根據國際糖尿病聯盟(IDF)預測,2022年全球糖尿病醫療費用將約為9,660億美元,較過去15年成長316%。
根據世界衛生組織(WHO)預測,2022年將有近130萬人死於慢性B型肝炎和C型肝炎感染,其中約2.54億人將死於B型肝炎,5,000萬人死於C型肝炎感染。世界衛生組織在報告中稱,2010年,估計有5.24億人年齡在65歲及以上,佔世界人口的8%,但到2050年,這一數字將幾乎增加兩倍,預計這一數字將達到約15億。
營養不良、缺乏運動和有害飲酒會導致心血管疾病、癌症和慢性呼吸道疾病等慢性疾病的發生,似乎將直接影響未來幾年的筆用針頭市場。
按地區分類,筆針市場分為北美、南美、歐洲、中東和非洲以及亞太地區。由於慢性疾病患者數量的增加,佩恩針在北美迅速流行。根據疾病管制與預防中心的數據,美國有 608,336 人死於癌症。對最大限度減少副作用的藥物輸送系統的需求迅速成長,推動了該國對筆用針頭的需求。
技術的進步和醫療保健成本的上升極大地推動了筆針市場的成長。例如,根據美國醫療保險和醫療補助服務中心的數據,2022 年美國醫療保健支出成長 4.1%,達到 4.5 兆美元。
在歐洲,各國政府正在放鬆監管並加速創新新藥的核准流程,以滿足人口老化日益成長的需求。該舉措旨在促進國內和國際製藥公司的發展,並吸引新業務進入歐洲市場。
此外,國內市場參與者以併購形式增加的策略投資預計將加劇競爭,預計將進一步推動未來幾年的市場成長機會。
此外,在亞太地區,人口健康意識的提高以及新型注射給藥系統和技術使用市場的快速發展預計將在預測期內推動市場成長。中國和印度政府正在推出新政策來改善公民健康,包括擴大公立醫療機構的保險覆蓋範圍和標準化服務。
為什麼要購買這份報告?
它有什麼用?
產業和市場考慮因素、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發和競爭影響。
The pen needle market is expected to grow at a CAGR of 9.27% over the forecast period to reach a total market size of US$3,189.012 million by 2030, increasing from US$2,046.792 million in 2025.
Pen needles are widely used to deliver injectable medication into the body. The rising prevalence of chronic disease is expected to be one of the prime drivers of market growth during the forecast period. However, the availability of substitutes is anticipated to restrain the market's growth in the coming years.
Pen Needle Market Drivers
The rising prevalence of chronic diseases such as cancer and diabetes is one of the prime drivers for the market growth during the forecast period. According to the International Diabetes Federation report, the number of people with diabetes under the age group of 20-79 years has risen from 425 million in 2017 to 537 million in 2022 and is expected to reach 783 million in 2045.
In addition, the rising economic burden of diabetes and increasing healthcare expenditure worldwide are also anticipated to increase the demand for rapid diagnostic kits for glucose monitoring in the coming years. According to the International Diabetes Federation (IDF), global healthcare expenditure on diabetes was around USD 966 billion in 2022, representing an increase of 316% over the last 15 years.
According to the World Health Organization (WHO), in 2022, nearly 1.3 million people died from chronic hepatitis B and C infection, and approximately 254 million people lived with hepatitis B, and 50 million people are living with hepatitis C. The WHO, in its report, stated that in 2010, an estimated 524 million people were aged 65 or older, which constitutes 8 percent of the world's population, and by 2050 this number is expected to nearly triple to about 1.5 billion, representing 16% of the world population.
Poor nutrition, physical inactivity, and the harmful use of alcohol contribute to the development of chronic conditions like cardiovascular diseases, cancer, and chronic respiratory disease, which will directly affect the market for pen needles in the coming years.
By geography, the pen needle market is segmented into North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The pen needle is fast gaining traction in North America due to the growing number of chronic disease cases. According to the United States Centre for Disease Control and Prevention, 6,08,336 people died due to cancer in the United States. The burgeoning need for a targeted drug delivery system that causes minimal side effects drives the demand for pen needles in the country.
Advancements in technology and increased healthcare spending have significantly boosted the pen needle market growth. For instance, U.S. healthcare spending increased by 4.1% to reach USD 4.5 trillion in 2022, as per the United States Centre for Medicare and Medicaid Services.
In Europe, the government is easing regulations and speeding up the approval process for innovative new drugs to meet the increasing needs of the aging population. This initiative aims to promote domestic and foreign pharmaceutical companies and attract new businesses to the European market.
In addition, increasing strategic investment by domestic market players in the form of mergers and acquisitions increases the competition, which is further expected to propel market growth opportunities in the coming years.
Furthermore, in the Asia Pacific region, increasing health awareness among the population and the rapid market evolution in using new injectable drug delivery systems or technologies are expected to drive market growth during the forecast period. The Chinese and Indian governments are establishing new policies to improve the population's health, including coverage expansion of public healthcare institutions and standardizing their services.
Reasons for buying this report:-
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence